Raymond James Financial’s Ascendis Pharma ASND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.4M Sell
6,144
-757
-11% -$192K ﹤0.01% 3785
2026
Q2
$1.84M Sell
6,901
-1,753
-20% -$409K ﹤0.01% 3544
2026
Q1
$1.98M Buy
8,654
+1,992
+30% +$447K ﹤0.01% 3370
2025
Q4
$1.42M Buy
6,662
+3,393
+104% +$701K ﹤0.01% 3538
2025
Q3
$650K Buy
3,269
+1,967
+151% +$367K ﹤0.01% 3960
2025
Q2
$225K Sell
1,302
-4,042
-76% -$658K ﹤0.01% 4453
2025
Q1
$833K Buy
+5,344
New +$763K ﹤0.01% 3614

Other funds holding ASND

Raymond James Financial's ASND Position: Q3 2026 in Review

Raymond James Financial reduced its Ascendis Pharma (ASND) stake by 11% in Q3 2026, selling an estimated $192K and leaving 6,144 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3785.

Raymond James Financial first reported a position in ASND in Q1 2025 and has held it in 7 quarters since. The position peaked at $1.98M in Q1 2026. 347 funds tracked by Wall St. Rank hold ASND as of Q3 2026.

  • Raymond James Financial held 6,144 shares of Ascendis Pharma worth $1.4M as of Q3 2026.
  • Raymond James Financial sold 757 Ascendis Pharma shares in Q3 2026, an estimated $192K.
  • Ascendis Pharma made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #3785 holding.
  • Raymond James Financial first reported a position in Ascendis Pharma in Q1 2025 and has held it in 7 quarters since.
  • Raymond James Financial's Ascendis Pharma position peaked at $1.98M in Q1 2026.
  • 347 funds tracked by Wall St. Rank held Ascendis Pharma as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.